Compound 2–75 is an enzalutamide hybrid with HDAC inhibitory activity that promoted p21, increased acetyl-tubulin levels (due to enhanced HDAC6 inhibition), and lowered Hsp90 and AR protein levels in C4-2 prostate cancer cells (Rosati et al., 2016). The gene discussed is HDAC6; the disease is prostate cancer.